Proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of a patient with dyslipidemia and myopathy
2019
Abstract
We present a 46-year-old patient with mixed dyslipidaemia and muscle pain. This patient, despite his low age, had a myocardial infarction and was subsequently indicated for the treatment of dyslipidaemia in secondary prevention.
Significant elevation of creatine kinase occurred at the beginning of statin therapy. For this reason statins were discontinued and the patient was referred to a lipidology clinic.
Ezetimibe and fenofibrate were used in the clinic. These drugs did not achieve the LDL-cholesterol target and therefore the proprotein convertase inhibitor subtilisin / kexin type 9 (PCSK9), with excellent tolerance and desirable reduction in LDL-cholesterol was chosen.